U.S. National Institutes of Health
U.S. National Institutes of Health


IDRankTitleRecruitmentStudy ResultsConditionsInterventionsURL
158611158611Study of Anxiety and Avoidance of Others in Patients Previously Treated for Head and Neck CancerCompletedNo Results AvailableAnxiety Disorder|Head and Neck Cancer|Lung CancerOther: Medical chart review|Other: Liebowitz Social Anxiety Scale and the Social Phobia and Anxiety Inventory|Procedure: management of therapy complications|Procedure: Structured Clinical Interview for the Diagnostic and Statistical Manual-IV SCID|Other: Functional Assessment of Cancer Therapy-General (FACT-G)https://ClinicalTrials.gov/show/NCT00483639
158612158612Hemodynamic Response After Six Months of SildenafilRecruitingNo Results AvailablePulmonary Arterial HypertensionDrug: oral sildenafilhttps://ClinicalTrials.gov/show/NCT00483626
158613158613Effects of Treatment of Chronic Stress in Patients With LupusCompletedNo Results AvailableSystemic Lupus ErythematosusBehavioral: Cognitive-behavioral therapy of Meichenbaumhttps://ClinicalTrials.gov/show/NCT00483613
158614158614Pharmacokinetic Study of Fondaparinux in Outpatients With Renal DysfunctionWithdrawnNo Results AvailableKidney DiseasesDrug: fondaparinuxhttps://ClinicalTrials.gov/show/NCT00483600
158615158615Does Heme Oxygenase-1 Induction Ameliorate Cardiac Injury After Myocardial Infarction?CompletedNo Results AvailableAcute Myocardial InfarctionDrug: Heme arginatehttps://ClinicalTrials.gov/show/NCT00483587
158616158616Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy ToddlersCompletedHas ResultsMeningococcal Meningitis|Measles|Mumps|Rubella|VaricellaBiological: Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|Biological: Measles-mumps-rubella-varicella vaccine|Biological: Routine paediatric vaccine - Pneumococcal conjugate (PCV) and Hepatitis Ahttps://ClinicalTrials.gov/show/NCT00483574
158617158617Gefitinib and Etoposide in Treating Patients With Advanced Prostate Cancer That Did Not Respond to Hormone TherapyActive, not recruitingNo Results AvailableProstate CancerDrug: etoposide|Drug: etoposide|Other: laboratory biomarker analysishttps://ClinicalTrials.gov/show/NCT00483561
158618158618Adjunctive Ziprasidone in the Treatment of Bipolar I DepressionCompletedHas ResultsBipolar Disorder|Depression, BipolarDrug: Ziprasidone|Drug: Placebohttps://ClinicalTrials.gov/show/NCT00483548
158619158619Oral Contraceptive Interaction Study for GW273225TerminatedNo Results AvailableHealthy Subjects|Bipolar DisorderDrug: GW273225https://ClinicalTrials.gov/show/NCT00483535
158620158620Telephone Intervention After Traumatic Brain InjuryCompletedNo Results AvailableBrain InjuriesBehavioral: Self-management telephone counselinghttps://ClinicalTrials.gov/show/NCT00483522
158621158621Study of NGR-hTNF in Combination With Doxorubicin in Patients Affected by Metastatic Small Cell Lung CarcinomaActive, not recruitingNo Results AvailableSmall Cell Lung CancerDrug: NGR-hTNF|Drug: Doxorubicinhttps://ClinicalTrials.gov/show/NCT00483509
158622158622Evaluation of the Protection Activity of Microfine Titanium Dioxide (Ti02), Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria (SU)CompletedHas ResultsIdiopathic Solar UrticariaDrug: Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209)|Drug: Ti02 pigmentary 3% alone (formula RV3131A-MV1211)|Drug: bisoctrizole 10% alone (formula RV3131A-MV1237)|Drug: Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)|Drug: Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329)|Drug: Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212)|Drug: Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]|Drug: V0096 CR vehicle (formula RV3131A-MV1197)https://ClinicalTrials.gov/show/NCT00483496
158623158623Project HERMITAGE: HIV Prevention in Hospitalized Russian DrinkersCompletedNo Results AvailableHIV InfectionsBehavioral: Individual and group HIV risk behavior counseling sessions|Behavioral: health education and support grouphttps://ClinicalTrials.gov/show/NCT00483483
158624158624Immunogenicity and Safety of Sanofi Pasteur's AVAXIM 80U Pediatric Vaccine Followed by Booster DoseCompletedNo Results AvailableHepatitis ABiological: Hepatitis A vaccine AVAXIM 80U|Biological: Hepatitis A vaccine (HAVRIX 720)https://ClinicalTrials.gov/show/NCT00483470
158625158625Effects of Epidermal Growth Factor Receptor Inhibitor Therapy in the Skin of Cancer PatientsCompletedNo Results AvailableSolid TumorDrug: enzyme inhibitor therapy|Genetic: protein expression analysis|Other: immunohistochemistry staining method|Other: laboratory biomarker analysis|Procedure: biopsyhttps://ClinicalTrials.gov/show/NCT00483457
158626158626Telephone Follow-Up on Outcome After Mild Traumatic Brain InjuryCompletedNo Results AvailableBrain ConcussionBehavioral: Scheduled telephone follow-uphttps://ClinicalTrials.gov/show/NCT00483444
158627158627Dose-Finding Study for Vitamin K2 in Human VolunteersCompletedNo Results AvailableVitamin K-StatusDietary Supplement: no vitamin K|Dietary Supplement: 10 mcg Vitamin K for 3 months daily|Dietary Supplement: 20 mcg Vitamin K for 3 months daily|Dietary Supplement: 45 mcg Vitamin K for 3 months daily|Dietary Supplement: 90 mcg Vitamin K for 3 months daily|Dietary Supplement: 180 mcg Vitamin K for 3 months daily|Genetic: 360 mcg Vitamin K for 3 months dailyhttps://ClinicalTrials.gov/show/NCT00483431
158628158628Survey of Testosterone Levels in Male Cancer PatientsCompletedNo Results AvailableHypogonadismhttps://ClinicalTrials.gov/show/NCT00483418
158629158629Oxaliplatin, Capecitabine, and Cetuximab in Treating Patients With Advanced Liver CancerCompletedNo Results AvailableLiver CancerBiological: cetuximab|Drug: capecitabine|Drug: oxaliplatinhttps://ClinicalTrials.gov/show/NCT00483405
158630158630Treatment of Hyperglycaemia and Insulin Resistance in HIV Infected PatientsCompletedNo Results AvailableInsulin ResistanceDrug: metformin, rosiglitazonehttps://ClinicalTrials.gov/show/NCT00483392
158631158631High Dose or High Dose Frequency Study of Alglucosidase AlfaCompletedHas ResultsPompe Disease|Glycogen Storage Disease Type II (GSD-II)|Glycogenesis 2 Acid Maltase DeficiencyBiological: alglucosidase alfahttps://ClinicalTrials.gov/show/NCT00483379
158632158632Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors (Closed to Accrual 12/11/2008)Active, not recruitingNo Results AvailableUnspecified Adult Solid Tumor, Protocol SpecificDrug: capecitabine|Drug: gemcitabine hydrochloride|Drug: imatinib mesylate|Genetic: mutation analysis|Genetic: nucleic acid sequencing|Genetic: polymerase chain reactionhttps://ClinicalTrials.gov/show/NCT00483366
158633158633Effect of a Nasal Bolus Allergen Challenge on Inflammatory MarkersCompletedNo Results AvailableSeasonal Allergic RhinitisProcedure: Intra-nasal allergen challenge with Phleum pratense.|Procedure: Collection of nasal effluent using filter paper.|Procedure: Measurement of nasal congestion using acoustic rhinometry.https://ClinicalTrials.gov/show/NCT00483353
158634158634Management of Atypical Endometrial Hyperplasia and Endometrial Carcinoma Using Megestrol AcetateCompletedNo Results AvailableAtypical Endometrial Hyperplasia|Endometrial CarcinomaDrug: Megestrol Acetatehttps://ClinicalTrials.gov/show/NCT00483327
158635158635Homocystinuria: Treatment With N-AcetylcysteineCompletedNo Results AvailableHomocystinuriaDrug: N-acetylcysteinehttps://ClinicalTrials.gov/show/NCT00483314
158636158636A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic MelanomaCompletedNo Results AvailableMalignant MelanomaDrug: Sorafenib (BAY 43-9006)|Drug: ABI-007(Abraxane)https://ClinicalTrials.gov/show/NCT00483301
158637158637Written Educational Information and Phone Calls in Increasing Follow-Up Care in Hispanic Women With Abnormal Pap SmearsCompletedNo Results AvailableCervical CancerOther: educational intervention|Other: questionnaire administration|Other: study of socioeconomic and demographic variables|Other: survey administrationhttps://ClinicalTrials.gov/show/NCT00483288
158638158638Fall Prevention by Alfacalcidol and TrainingWithdrawnNo Results AvailableAccidental Falls|Chronic Renal Insufficiency|AgedDrug: Alfacalcidol|Behavioral: Balance, gait and strength training|Behavioral: Patient educationhttps://ClinicalTrials.gov/show/NCT00483275
158639158639Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple MyelomaCompletedHas ResultsMultiple MyelomaDrug: CCI-779|Drug: Bortezomibhttps://ClinicalTrials.gov/show/NCT00483262
158640158640Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic AneurysmRecruitingNo Results AvailableThoracoabdominal Aortic Aneurysm|Paravisceral Abdominal Aortic AneurysmDevice: Endovascular Branched Stent-Grafthttps://ClinicalTrials.gov/show/NCT00483249

* Görseller ve İçerik tekif hakkına sahip olabilir